These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 16422890)
21. Pharmacokinetic comparison of two nicotine transdermal systems, a 21-mg/24-hour patch and a 25-mg/16-hour patch: a randomized, open-label, single-dose, two-way crossover study in adult smokers. DeVeaugh-Geiss AM; Chen LH; Kotler ML; Ramsay LR; Durcan MJ Clin Ther; 2010 Jun; 32(6):1140-8. PubMed ID: 20637967 [TBL] [Abstract][Full Text] [Related]
22. Transdermal androgens: pharmacology and applicability to hypogonadal elderly men. Swerdloff RS; Wang C J Endocrinol Invest; 2005; 28(3 Suppl):112-6. PubMed ID: 16042369 [TBL] [Abstract][Full Text] [Related]
23. Optimal diagnostic measures and thresholds for hypogonadism in men with HIV/AIDS: comparison between 2 transdermal testosterone replacement therapy gels. Blick G Postgrad Med; 2013 Mar; 125(2):30-9. PubMed ID: 23816769 [TBL] [Abstract][Full Text] [Related]
24. Enhanced transdermal delivery of testosterone across nonscrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men. Meikle AW; Mazer NA; Moellmer JF; Stringham JD; Tolman KG; Sanders SW; Odell WD J Clin Endocrinol Metab; 1992 Mar; 74(3):623-8. PubMed ID: 1740497 [TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics and metabolism of a permeation-enhanced testosterone transdermal system in hypogonadal men: influence of application site- -a clinical research center study. Meikle AW; Arver S; Dobs AS; Sanders SW; Rajaram L; Mazer NA J Clin Endocrinol Metab; 1996 May; 81(5):1832-40. PubMed ID: 8626843 [TBL] [Abstract][Full Text] [Related]
26. Re: Ebert T, Jockenhövel F, Morales A, Shabsigh R. The current status of therapy for symptomatic late onset hypogonadism with transdermal testosterone gel. Eur Urol 2005;47:137-46. Ponholzer A; Rauchenwald M; Madersbacher S Eur Urol; 2005 Jul; 48(1):170-1; author reply 171. PubMed ID: 15967269 [No Abstract] [Full Text] [Related]
27. Preventing secondary exposure to women from men applying a novel nestorone/testosterone contraceptive gel. Yuen F; Wu S; Thirumalai A; Swerdloff RS; Page ST; Liu PY; Dart C; Wu H; Blithe DL; Sitruk-Ware R; Long J; Bai F; Hull L; Bremner WJ; Anawalt BD; Wang C Andrology; 2019 Mar; 7(2):235-243. PubMed ID: 30556332 [TBL] [Abstract][Full Text] [Related]
29. Safety and efficacy of testosterone gel in the treatment of male hypogonadism. Lakshman KM; Basaria S Clin Interv Aging; 2009; 4():397-412. PubMed ID: 19966909 [TBL] [Abstract][Full Text] [Related]
30. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison. Likar R; Lorenz V; Korak-Leiter M; Kager I; Sittl R Clin Ther; 2007 Aug; 29(8):1591-606. PubMed ID: 17919542 [TBL] [Abstract][Full Text] [Related]
31. One-year efficacy and safety study of a 1.62% testosterone gel in hypogonadal men: results of a 182-day open-label extension of a 6-month double-blind study. Kaufman JM; Miller MG; Fitzpatrick S; McWhirter C; Brennan JJ J Sex Med; 2012 Apr; 9(4):1149-61. PubMed ID: 22321357 [TBL] [Abstract][Full Text] [Related]
32. Reduction in 24-hour plasma testosterone levels in subjects who showered 15 or 30 minutes after application of testosterone gel. de Ronde W; Vogel S; Bui HN; Heijboer AC Pharmacotherapy; 2011 Mar; 31(3):248-52. PubMed ID: 21361734 [TBL] [Abstract][Full Text] [Related]
33. Rationale, design and methods of the ESPRIT study: Energy, Sexual desire and body PropoRtions wIth AndroGel, Testosterone 1% gel therapy, in hypogonadal men. Behre HM; Heinemann L; Morales A; Pexman-Fieth C Aging Male; 2008 Jun; 11(2):101-6. PubMed ID: 18570063 [TBL] [Abstract][Full Text] [Related]
34. Efficacy of changing testosterone gel preparations (Androgel or Testim) among suboptimally responsive hypogonadal men. Grober ED; Khera M; Soni SD; Espinoza MG; Lipshultz LI Int J Impot Res; 2008; 20(2):213-7. PubMed ID: 17898800 [TBL] [Abstract][Full Text] [Related]
35. Safety and efficacy of testosterone gel 1% augmentation in depressed men with partial response to antidepressant therapy. Orengo CA; Fullerton L; Kunik ME J Geriatr Psychiatry Neurol; 2005 Mar; 18(1):20-4. PubMed ID: 15681624 [TBL] [Abstract][Full Text] [Related]
36. Levonorgestrel implants (Norplant II) for male contraception clinical trials: combination with transdermal and injectable testosterone. Gonzalo IT; Swerdloff RS; Nelson AL; Clevenger B; Garcia R; Berman N; Wang C J Clin Endocrinol Metab; 2002 Aug; 87(8):3562-72. PubMed ID: 12161475 [TBL] [Abstract][Full Text] [Related]
37. Testim 1% testosterone gel for the treatment of male hypogonadism. Bouloux P Clin Ther; 2005 Mar; 27(3):286-98. PubMed ID: 15878382 [TBL] [Abstract][Full Text] [Related]
38. Absorption of testosterone gel 1% (Testim) from three different application sites. Guay AT; Smith TM; Offutt LA J Sex Med; 2009 Sep; 6(9):2601-10. PubMed ID: 19549089 [TBL] [Abstract][Full Text] [Related]
39. Testosterone gel monotherapy improves sexual function of hypogonadal men mainly through restoring erection: evaluation by IIEF score. Chiang HS; Cho SL; Lin YC; Hwang TI Urology; 2009 Apr; 73(4):762-6. PubMed ID: 19118875 [TBL] [Abstract][Full Text] [Related]
40. Does sildenafil combined with testosterone gel improve erectile dysfunction in hypogonadal men in whom testosterone supplement therapy alone failed? Greenstein A; Mabjeesh NJ; Sofer M; Kaver I; Matzkin H; Chen J J Urol; 2005 Feb; 173(2):530-2. PubMed ID: 15643239 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]